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Effect of ACE inhibitors on atrial natriuretic factor in the brains of rats
with reduced renal mass. We tested the effect of renal insufficiency, with
and without angiotensin (Ang) converting enzyme (ACE) inhibition, on
blood and brain atnal natriuretic factor (ANF) in rats. Two ACEs, one
which penetrates into the CNS and one which does not, were used to
distinguish between peripheral and central ACE effects. Rats under-
went 5/6 nephrectomy (5/6-NPX) by ligation of renal arterial branches.
After seven days, 28 5/6-NPX rats received lisinopril 20 mg/kg/day and
28 5/6-NPX rats received quinapril 30 mg/kg/day orally for five days,
while 28 5/6-NPX control rats and 28 sham rats did not. Body weight,
blood pressure, drinking and urine volume were monitored. At sacri-
fice, urine, plasma, and brain tissue was collected. ANF in 16 brain
areas was measured by radioimmunoassay. 5/6-NPX resulted in in-
creased blood pressure, increased urine volume, proteinuria, and
increased drinking. Both ACEs lowered blood pressure to sham values
and decreased proteinuria. Both ACEs increased plasma renin activity
and decreased plasma ANF. However, only lisinopril decreased drink-
ing and urine volume. 5/6-NPX increased ANF values in six brain areas,
namely the periventncular preoptic nucleus, the arcuate nucleus, the
perifornical nucleus, the penventncular hypothalamic nucleus, the
paraventricular nucleus, and the dorsal raphe nucleus compared to
sham rats. These same increases in brain ANF were also observed in
5/6-NPX rats given quinapril, compared to shams. However, lisinopril
lowered ANF to sham levels in the periventricular preoptic nucleus, the
arcuate nucleus, and the perifornical nucleus. In the three additional
brain areas, namely the periventricular hypothalamic nucleus, the
paraventricular nucleus, and the dorsal raphe nucleus, lisinopril did not
effect the elevated ANF concentrations. The data suggest that 5/6-NPX
increases ANF in six brain areas, independent of blood pressure. The
increased urine volume and increased drinking associated with 5/6-NPX
are at least in part mediated centrally. ANF may play a role in drinking
behavior and volume homeostasis in certain brain areas. Furthermore,
ANF in three of these areas may be influenced by Ang IT-related
mechanisms.
ventral wall of the third ventricle [3, 4]. This area, which is also
known as the AV3V region, is important in the regulation of
both salt and water intake and blood pressure [5—8]. Further,
aldosterone administration increases ANF in both the organum
vasculosum laminae terminalis and periventricular preoptic
nucleus of the adrenalectomized rat, while dexamethasone does
not [91. These observations suggest a role for ANF within the
AV3V in the regulation of salt and water homeostasis.
Angiotensin II (Ang II), which is important in blood pressure
regulation in both the periphery and the brain, plays an impor-
tant role in modulating the urge to drink [10]. Rats with
decreased renal function exhibit increased drinking and relative
polyuria. Enalapril was found to control drinking behavior in
dialysis patients, while decreasing Ang II levels [11]. We
addressed the hypothesis that the thirst stimulus observed with
chronic renal failure involves Ang II and ANF within the brain.
To elucidate their interrelationship, we investigated rats with
reduced renal mass following Ang II converting enzyme (ACE)
inhibition. We purposely selected lisinopril, the lysine salt of
enalaprilat, because two different groups of investigators found
that lisinopril was superior to other ACE inhibitors in inhibiting
ACE in the brain [12—14]. This property of lisinopril may be
related to the presence of an aminobutyl side chain [14]. To
control for the effects on blood pressure produced by reduced
renal mass as well as for peripheral ACE inhibition, we gave
quinapril, which is active only outside the blood brain barrier
[15].
Methods
Animal models and procedures
Atrial natriuretic factor (ANF) has potent renal, adrenal, and
vascular actions on electrolyte homeostasis and blood pressure
[1]. Similar materials have been located at other sites, including
the kidney [2] and the brain [3, 4]. There, the most prominent
group of ANF-containing neurons is found in the periventricu-
lar preoptic and hypothalamic areas, adjacent to the antero-
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Male Wistar rats weighing 225 g (Savo-Ivanovas, Kisslegg,
Germany) were obtained. The animals were fed a standard rat
chow (Altromin, Lage, Germany), which contains 1 g Na per kg
diet. The animals were housed in an approved facility at 22°
1°C and at a humidity of 60%. The protocol was approved and
sanctioned according to the requirements of the American
Physiological Society. Under pentobarbital anesthesia (60 mgI
kg) rats were either sham operated or underwent a reduction in
renal mass by a 5/6 nephrectomy (5/6-NPX) procedure as
outlined elsewhere [16]. Briefly, the left kidney was mobilized
with care being observed not to injure the adrenal gland. Two to
three twigs of the renal artery were laid free and carefully
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occluded with a fine suture. The bulk of the kidney was
observed to blanch. The kidney on the opposite side was
subsequently removed. 5/6-NPX rats were randomly distrib-
uted to three groups of 28 rats each. Twenty-eight sham
operated rats were prepared.
The animals were returned to their cages and allowed free
access to food and water for seven days. Lisinopril or quinapril
were added to the drinking water of two 5/6-NPX groups in
sufficient quantities to provide approximately 20 mg/kg/day and
30 mg/kg/day, respectively, of each ACE inhibitor for an
additional five days. Since brain areas from four rats were
pooled for each brain ANF determination, a total of 28 rats was
used per group. The four groups studied were control, 5/6-NPX,
5/6-NPX + lisinopril and 5/6-NPX + quinapril. The rats were
housed in metabolism cages to acclimatize them for urine
collections. The rats were weighed, and blood pressure was
measured by the indirect, tail cuff method after 5/6-NPX and on
the day of sacrifice. Consumption of drinking water was mon-
itored as well. Twenty-four hour urine specimens for protein
and electrolyte excretion were collected on the day of sacrifice.
Plasma values were also determined on day of sacrifice.
Determination of plasma and urine values
The animals were anesthetized with pentobarbital (60 mg/kg)
and blood was obtained after decapitation. Hematocrit was
determined by an automated method (ELT 8, Fa. Moltronic,
Heidelberg, Germany), plasma osmolality was measured by
freezing point depression (Osmomat, Fa. Gonotec, Berlin,
Germany), sodium and potassium were determined by flame
photometry (AFM 2, Eppendorf Co., Hamburg, Germany).
Creatinine and phosphate were measured by automated tech-
niques. Protein in urine was measured by the biuret method.
Creatinine, sodium, potassium, and osmolality were measured
as above.
For PRA determinations, the blood was collected into pre-
chilled (4°C) polypropylene tubes, which contained a solution of
5% 125 mrsi EDTA. After centrifugation (6000 g, 10 mm at 4°C)
plasma was stored at —20°C until assay. PRA was determined
by measuring the Ang I generation by radioimmunoassay [17].
For the determination of ANF, the blood collected in tubes
containing 500 KIU aprotinin (Trasylol®, Bayer AG, Le-
verkusen, Germany) and immediately centrifuged (2000 g, 10
mm, at 4°C). The plasma was stored at —70°C until assay. ANF
was extracted from plasma according to the method of Larose
et a! [18], which we modified in a few details. Plasma samples (1
ml) were acidified to pH 3 to 4 with 2 N HC1. The samples were
applied to Sep Pak C 18 reverse-phase octadodecyl silane car-
tridge columns (Waters Associates, Milford, Massachusetts,
USA) that had been activated earlier with 100% methanol (10
ml) followed by 5% acetic acid (10 ml). After washing with
trifluoracetic acid (TFA, 3 to 5 ml), the peptide was eluted with
a mixture of 60% acetonitrile in 0.1% TFA (2 ml). The eluates
were evaporated to dryness with nitrogen, and the residue was
reconstituted with 1 ml of RIA buffer (50 m potassium
phosphate buffer, pH 7.4, containing 0.1% BSA, 0.02 NaN3, 50
mM NaC1, 0.1% Triton X-lQ0, 50 M phenylmethylsulfonyl
fluoride and 10 sM aprotinin) for ANF determination by radio-
immunoassay.
Tissue dissection and extraction of brain ANF
The animals were decapitated between 8:00 and 10:00 a.m.;
the brains were quickly removed and frozen on dry ice. Serial
coronal sections of 300 m thickness were cut with a cryostat at
—10°C and 18 brain regions were removed by the micropunch
technique [19]. The brain regions represented those with func-
tional systems which were mainly involved in the regulation of
electrolyte and volume homeostasis, as well as blood pressure.
Tissue pellets of identical brain nuclei from four animals were
pooled and six assay sets per group were developed (4 x 24 rats
each). The samples were collected in 1.5 ml conical Eppendorf
tubes containing 60 p1 0.1 N HCI and placed in a boiling water
bath for 10 minutes. After the addition of 100 p1 RIA-buffer, the
samples were homogenized and 20 p1 aliquots of the homoge-
nates were removed for the determination of protein content by
the Lowry method [20]. The remaining sample was centrifuged
at 2000 g for 15 minutes at 4°C and 100 p1 of the supernatant
fluid was used for ANF determinations by radioimmunoassay.
Measurement of plasma and brain ANF concentrations
For determination of plasma ANF and brain ANF values, a
commercially available radioimmunoassay kit was used (Penin-
sula Labs., Inc., Belmont, California, USA). The cross reac-
tivity of this antibody for rat ANF in plasma and brain has been
outlined in detail elsewhere [8]. The reconstituted plasma and
brain extracts (100 p1) were incubated with the same volume of
antiserum. Synthetic human ANF ranging from 1-128 pg/tube
was incubated as the standard. After incubation for 24 hours at
4°C, 100 p1 of the ANF-tracer '25J-human ANF was added.
After another 24 hours of incubation, goat anti-rabbit IgG serum
and normal rabbit serum (100 p1, dissolved in RIA buffer) were
added and the mixture was incubated at room temperature for
two hours. Then 500 p1 RIA buffer was added, the contents
were vortex mixed and centrifuged (2000 g, 20 mm, at 4°C).
After centrifugation, the supernatants were separated and the
precipitates were counted in a gamma counter. The sensitivity
of this assay was 1.5 pg/tube. The recovery of added ANF
standard was 79 3%; the intra- and intercoefficients of
variation were 9 and 14%, respectively. Serial dilutions of
plasma and brain extracts showed parallelism to the synthetic
ANF standards.
Statistical analysis
The results are expressed as mean standard error of the
mean (sEM). The data were examined by analysis of variance
and two-tailed unpaired Students t-test with Bonferoni's cor-
rection. Differences at the 95% level of confidence (P < 0.05)
were considered to be significant. All results presented as
increases, decreases, or changes in the text and tables met these
criteria.
Results
Table 1 shows the effects on body weight, urine, and plasma
values of sham rats, 5/6-NPX rats, and 5/6-NPX rats with
lisinopril or quinapril treatment. Sham rats weighed more than
all other groups, whereas 5/6-NPX rats weighed less than all
other groups. 5/6-NPX resulted in increased blood pressure
which was effectively reduced by both lisinopril and quinapril.
5/6-NPX resulted in increased water intake and urine volume,
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Table 1. Characteristics (mean saM) of normal rats, 5/6-nephrectomized (5/6-NPX) rats with reduced renal mass,
lisinopril-treatmeut (NPX + L), and NPX-rats with quinapril treatment (NPX + Q) at sacrifice
5/6-NPX-rats wth
Controls 5/6-NPX NPX + L NPX + Q
Body weightg
Systolic blood pressure mm Hg
263 2
121 2
209 6
150 3
265 5
105 4ab
225 ia
107 3ab
Water intake ml 28.1 1.2 39.9 6,4a 32.7 2.7 40 3
Urine values
Urine volume ml 9.0 0.5 37.4 6.9a 20.7 27ab 35 7ac
Urine osmolality mOsm/lirer
Urine sodium concentration mmol/liter
3335 132
142 7
700 97
20 ioa
1301 l36a55 lO 978 8726 16
Proteinuria mg/day 10 6 97 36 42 20a 18 2bc
Plasma values
Plasma sodium mmol/liter 147 2 148 1 149 1 151 3
Plasma potassium mmol/liter 5.9 0.2 5.2 o,sa 5.8 0.2 5.4 0.7
Plasma calcium mmolf liter 2.6 0.2 2.6 0.1 2.9 0.1 2,9 0.1
Plasma phosphate mmol/liter
Plasma BUN mg/dl
2.83 0.10
24 1
1.90 0,lOa56 a 2.32 0.2069 5b 2.32 0.2061 4
Plasma creatinine mg/dl
Plasma renin activity ng Al/mI/hr
Plasma ANF pg/mI
0.35 0.10
4.5 0.7
52 5
0.65 0.06
1.6 0,6
107 8
0.83 0.06"
16.6 4.2a
26 3b
0.60 0.03
14.5 4,0ab21 4
P < 0.05: group differs from control; b group differs from 5/6-NPX; NPX + L differs from NPX + Q.
Table 2. Concentrations of ANF in selected brain areas of controls, 5/6-nephrectomized rats (5/6-NPX) and 5/6-nephrectomized rats with
lisinopril (NPX + L) or quinapnl (NPX + Q) treatment (pg ANF/mg protein; mean saM)
Brain area Controls 5/6-NPX NPX + L NPX -- Q
Periventr. preopt. nucl. 123.4 26.8 237.6 23.4a 150.4 11.2" 313.3 28.1
Perifornical nucl. 73.3 7.8 112.8 9,6a 65.3 9.5" 129.9 ac
Arcuate nucl. 115.2 10.4 262.6 29.Sa 133.4 24.71" 205.2 7.6
Periventr. hypoth. nucl. 130.2 13.8 181.3 I1.9 207.7 35,9a 277.3 23,5a
Paraventricularnuel, 121.7 11.7 196.1 13,7a 181.5 24.6a 180.7 21,6a
Dorsal raphe nucl. 79.9 8.2 132.3 16,9a 124.5 21,5a 153.2 l4.6a
Locus coeruleus 38.3 4.8 37.6 7.5 44.3 9.1 79,3 4.3
Cerebral cortex 26.7 1.9 26.4 2.0 29.7 3.9 29.4 2.3
Medial preopt. nucl. 90.5 4,3 127.4 17.7 120.9 11.4 119.0 14.4
Caudate/Putamen 5.7 1.0 4.9 0.8 5.3 0.8 7.1 0.9
Subfornical organ 54.3 19.3 34.3 9.4 37.7 3.8 47.0 8.3
Central amygd. nucl. 40.8 1.8 43. 6.0 49.4 3.6 54.4 10.3
Median eminence 163.6 13.5 186.6 24.1 209.3 32.8 232.5 18.4
Substantia nigra 17.5 1.6 21.5 6.0 19.9 3.3 23.8 1.7
Tegmentum pontis 67.8 4.1 90.6 13.9 68.5 5.6 131.5 11.7
NucI. of the solitary tract 33.5 5.1 32.6 3.9 26.5 10.6 32.9 5.7
P < 0.05; a group differs from control; b group differs from 5/6-NPX; "NPX + L differs from NPX + Q.
which were reduced, albeit not to control values with lisinopril,
but not by quinapril. Factoring the urine volume for body
weight did not affect the statistical analysis. Urine osmolality
and urine sodium concentration decreased with 5!6-NPX corre-
sponding to the increase in water intake and urine volume.
These changes were partially, but significantly reversed with
lisinopril, but not by quinapril. 516-NPX resulted in increased
proteinuria; the effect was reversed by lisinopril and even more
effectively by quinapril.
Changes in plasma Na were small and inconsistent. Plasma K
and phosphate were significantly reduced by 5/6-NPX. Lisino-
pril and quinapril both increased plasma K to control values.
Plasma Ca was not significantly affected. Creatinine values
measured after 5/6-NPX, but before treatments were given
(data not shown), revealed no significant differences between
the groups. The increase in BUN and creatinine values in the
516-NPX group was not reversed by either lisinopril or
quinapril. PRA was decreased by 5/6-NPX compared to con-
trols; both ACE inhibitors increased PRA above control values
in rats with 5/6-NPX. Plasma ANF was increased by 5/6-NPX.
5/6-NPX plus either ACE inhibitor was associated with a
marked decrease in circulating ANF concentrations.
Table 2 shows the brain ANF concentrations expressed as pg
ANF/mg protein in 16 different brain areas at sacrifice. 5/6-NPX
resulted in an increase in brain ANF in three different brain
areas in which the administration of lisinopril decreased the
ANF values to control levels. These three nuclei were the
periventricular preoptic nucleus, the perifornical nucleus, and
the arcuate nucleus. In three other brain areas 5/6-NPX resulted
in an increase in brain ANF values, which were not reduced by
lisinopril. These three areas were the periventricular hypotha-
lamic nucleus, the paraventricular nucleus, and the dorsal raphe
nucleus, The addition of quinapril, on the other hand, did not
alter the increases in brain ANF evoked by 5/6-NPX, which
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were consistent with the changes observed with NPX alone.
Interestingly, ANF within the locus coeruleus was increased in
the presence of quinapril compared to all other groups. Neither
5/6-NPX nor lisinopril influenced ANF values within the locus
coeruleus.
Discussion
Decreased renal mass by 5/6-NPX caused an increase in
blood pressure, increase in water intake, increased urine vol-
ume, decreased urine osmolality and increased proteinuria,
even over the relatively short 12-day time course of these
studies. Such changes are known sequels to 5/6-NPX and have
been reported elsewhere [21]. ACE inhibitors are effective
treatment in rats with 516-NPX. They reduce blood pressure,
proteinuria, and favorably influence the course of renal insuffi-
ciency compared to other blood pressure-reducing regimens
[21]. 5/6-NPX resulted in increased circulating ANF concentra-
tions and decreased plasma renin activity in our rats. The
elevated blood pressure and expanded extracellular fluid vol-
ume may have contributed to increased atrial pressure; both
effects are associated with increased ANF release [11. We have
previously observed similar effects of 516-NPXon plasma ANF
values [22]. ACE inhibition effectively reduced these elevated
ANF values to control levels, both in this and in our earlier
study [22].
Although lisinopril appears not to cross the blood brain
barrier as well as perindopril [15], convincing data indicate that
lisinopril is active centrally, perhaps related to its aminobutyl
side chain [14]. For instance, Sakaguchi et al [23] found that
lisinopril markedly reduced converting enzyme activity in the
circumventricular organs and other brain areas, four hours after
administration. Quinapril, on the other hand, was found not to
cross the blood brain barrier [15]. Since both lisinopril and
quinapril lowered blood pressure, decreased proteinuria, in-
creased plasma renin activity and decreased circulating ANF
equally well, we conclude that the effects on drinking and urine
volume were most likely mediated by central effects of lisino-
pril.
Ang II in the brain plays an important role in drinking
behavior and salt appetite. Small amounts of Ang II injected
into the cerebral ventricles results in an immediate drinking
urge in the rat [24]. Drinking behavior is increased by Ang II in
humans as well. Dialysis patients frequently drink water to
excess, an effect which is ameliorated with the administration of
enalapril [11]. The site of these actions is in part the AV3V area,
the importance of which has been discussed in detail elsewhere
[5]. Water intake and urine volume were significantly reduced in
516-NPX rats with lisinopril, but were not influenced by
quinapril. We are unable to distinguish between effects on
drinking behavior or those possibly mediated by the release of
arginine vasopressin in our animals. Vasopressin was not
measured in this study; however, in another investigation we
measured AVP in response to chronic peripheral and central
Ang II infusion in rats. In that study, we found that chronic
central Ang II actually decreased plasma vasopressin values
[25]. Thus, it is possible that some of the effects found here may
be related to enhanced AVP release.
Important new findings in this study were the increases in
ANF observed in six brain nuclei following 516-NPX and the
influence of ACE inhibition on these values. The fact that these
same elevations were observed in rats given quinapril, suggests
that neither peripheral Ang II nor hypertension per se was
responsible. The rats with 516-NPXhad free access to water and
displayed a normal serum osmolality. We have subsequently
performed additional studies in rats with hyperosmolality in-
duced by both water deprivation and hypertonic saline admin-
istration, and found that both maneuvers increase ANF in brain
nuclei, similar to the responses reported here (Bahner et al,
manuscript in preparation). The receptor distribution of ANF
containing nuclei overlaps that of Ang II [26]. ANF concentra-
tions in numerous brain nuclei are influenced by Na intake [7],
mineralocorticoid hormones [7], and modulation of the renin-
angiotensin system [8]. Further, the central administration of
ANF has substantial peripheral actions. For instance, Rohm-
eiss, Demmert and Unger [27] and Israel, Ton-es and Barbella
[28] reported an antinatriuretic effect in rats following the direct
administration of ANF into the brain, which was in part
mediated via activation of the renal nerves [27]. Central ANF
has also been shown to inhibit Ang Il-induced drinking [29], salt
appetite [30], pressor responses [31], vasopressin release [32],
and ACTH secretion [33]. In addition, Lee et a! [34] gave ANF
intracerebroventricularly in both rats and sheep. They found
that central ANF increased urine volume four- to sixfold above
baseline, without influencing electrolyte excretion. These find-
ings demonstrate a close, and perhaps inverse functional rela-
tionship between brain ANF and brain Ang II [35].
5/6-NPX resulted in increased ANF concentrations which
were reversed by lisinopril, namely in the periventricular pre-
optic nucleus, the perifornical nucleus, and the arcuate nucleus.
We hypothesize that ANF concentrations and their function
may be influenced by Ang Il-related mechanisms in these areas.
There is reason to speculate about such interrelationships
between these nuclei. For instance, the periventricular preoptic
nucleus is an integral part of the AV3V region. Gambino and
Felix [36] found that this nucleus was sensitive to blood
pressure changes induced by peripheral Ang II. The periven-
tricular preoptic nucleus has bidirectional neuronal connections
with the subfornical organ. Although the subfornical organ has
no ANF containing cell bodies [37] and shows a low density of
ANF-containing nerve fibers [38], it has a plethora of ANF
receptors [39]. Blood-borne Ang II may penetrate the fenes-
trated capillaries of the subfornical organ and activate its
receptors at this site. Information may be conducted via Ang
Il-containing fibers through the lamina terminalis to the preop-
tic nucleus and subsequently to the perifornical nucleus and the
arcuate nucleus, both of which showed altered ANF concen-
trations to the maneuvers conducted here. The perifornical
nucleus is also involved in drinking behavior [40]. Moreover, it
possesses ANF-containing neurons which are distinct from
those in the preoptic nucleus. Large, multipolar neurons which
stain strongly for ANF [41] make up about 30% of the entire cell
population of this structure. Ang Il-containing neuronal projec-
tions between the perifornical nucleus and the subfornical organ
also have been described [42].
We suggest that the association between altered ANF con-
centrations in the brain and the changes we observed in urine
volume and drinking behavior raise the possibility of cause and
effect. However, we admit that the data require considerable
caution until direct intervention studies with microdialysis of
ANF into specific nuclei of the central nervous system are
28 Geiger et a!: Effect of ACE inhibitors on brain ANF
performed. The impairment in renal function was not uniform in
the three NPX groups, which could have also influenced the
central ANF values. Nevertheless, it is doubtful that the lower
level of renal function in the lisinopril group was responsible for
reducing brain ANF values to normal in three brain areas.
We did not measure central Ang II concentrations in the
brain, nor did we determine central ACE activity. Ang II has
been measured directly in rat brain tissue; however, the values
lie in the femtomolar range and require that the brains of 10 rats
be pooled for measurement (D. Ganten, Max DelbrOck Center
for Molecular Medicine, personal communication). The preci-
sion of current methods and the amount of tissue required do
not permit us to make such measurements in our model. In
addition, we did not measure kinins in blood or brain. The role
of the kinin system in our results cannot be addressed from our
data, Thus, we cannot say for certain that the effects on central
ANF we observed were related to lowered central Ang II
values. It is also possible that ACE inhibition altered Ang
Il-receptor binding. Berecek et al examined such binding in
SHR treated with captopril for a lifetime and also studied Ang
Il-receptor binding in cell culture. They found that ACE inhi-
bition decreased Ang Il-receptor binding 1431. The fact that
quinapril had no effect on increased central ANF concentra-
tions in response to 516-NPX suggests that lisinopril exerted its
effects via a direct central action. Although circulating Ang II
may exert central effects by stimulating brain receptors outside
the blood brain barrier [10], quinapril treatment had no effect on
the changes in brain ANF evoked by 5/6-NPX. However, one
notable effect of quinapril treatment on brain ANF was the
increase we observed in the locus coeruleus. We cannot ex-
clude a direct central effect of quinapril, nor can we state for
certain that the drug did not influence central Ang II values.
However, we believe the effects on the locus coeruleus may
have been indirect. The locus coeruleus is a relatively small, but
tightly packed group of primarily norepinephrine-containing
neurons in the pontine tegmentum. In an earlier study, we
found that ANF in the locus coeruleus was elevated in DOC-
salt and in 1K-lC Goldblatt hypertension [44]. Both conditions
are associated with low renin values and increased sympathetic
activity. To what extent quinapril may have influenced such
factors while lisinopril did not, cannot be answered from this
study.
Three additional brain areas demonstrated clear increases in
ANF values with 5/6-NPX; however, the administration of
lisinopril afforded no reduction in the ANF concentrations in
the periventricular hypothalamic nucleus, the paraventricular
nucleus, and the dorsal raphe nucleus. Presumably, the ANF
increases in these areas are not dependent upon Ang Il-related
mechanisms. Further, neither lisinopril nor quinapril had an
influence on ANF concentrations in 10 other brain areas tested,
in which 5/6-NPX did not influence brain ANF levels.
In summary, S/6-NPX in rats caused increased blood pres-
sure, drinking, urine volume, protein excretion, and circulating
ANF concentrations. ACE inhibition with lisinopril and
quinapril normalized blood pressure, reduced proteinuria, and
lowered circulating ANF values in rats with 5/6-NPX. How-
ever, lisinopril also decreased water intake and lowered urine
volume, while quinapril did not. The effects of lisinopril were
only partial; a diuresis related to increased solute excretion per
remaining nephron in the face of decreased renal mass re-
mained. Lisinopril also reverted 5/6-NPX-induced increases in
ANF concentrations in AV3V-associated brain nuclei. We
suggest that the increased drinking observed in this model was
at least in part the result of central Ang Il-mediated actions
within the brain involving the AV3V area and its interconnec-
tions. Moreover, ANF-containing neurons and pathways were
likely to be involved. It is possible that the increased ANF
values in these areas resulted in response to local actions of Ang
II in order to modulate its effects. The inhibitory effect that
central ANF has on Ang Il-mediated drinking [29] would
support such a view.
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